Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates

Financial Performance - Keros Therapeutics reported a quarterly loss of $0.18 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.11, representing an earnings surprise of +83.78% [1] - The company posted revenues of $14.26 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 86.04%, compared to revenues of $0.39 million in the same quarter last year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.11 on revenues of $7.67 million, while for the current fiscal year, the estimate is $0.33 on revenues of $235.61 million [7] - The estimate revisions trend for Keros Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - Keros Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Keros Therapeutics' stock may be influenced by the overall industry outlook, as the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by more than 2 to 1 [8]